"Scientists Create First Mathematical Model That Predicts Immunotherapy Success"
Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature. The proposed mathematical model, which captures aspects of the tumor's evolution and the underlying interactions of the tumor with the immune system, is more accurate than previous genomic biomarkers in predicting how the tumor will respond to immunotherapy. "We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors," said Benjamin Greenbaum, PhD, assistant professor of medicine, hematology, medical oncology, oncological services, and pathology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors." This novel model also has the potential to help find new therapeutic targets within the immune system and to help design vaccines for patients who do not typically respond to immunotherapy.
- Benjamin Greenbaum, PhD, Assistant Professor, Medicine, Hematology, Medical Oncology, Oncological Services, Pathology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai